Wael Fayad
Direktor/Vorstandsmitglied bei Crown Laboratories, Inc.
Profil
Mr. Fayad is a Managing Director at Hildred Capital Management, where he currently serves on the Board of Directors of three Hildred portfolio companies: Project Natural, Carlin Consumer Health, and Crown Laboratories.
Mr. Fayad previously served in an operating role at Hildred Capital Partners, closely involved with certain Hildred portfolio companies, leveraging his depth of experience to enhance strategic positioning, operational efficiency and overall growth trajectory, most notably as Chief Business Officer of Crown Laboratories.
Prior to Hildred, Mr. Fayad spent more than 25 years in pharma and biotech where he started his career in sales, marketing, and new products at Novartis and then Schering-Plough.
He worked at Forest Laboratories Inc. for 14 years and served as Corporate Vice President of Business Development.
After leaving Forest, he advised and worked with biotech and start-up life sciences companies including co-founding Accoy Pharmaceuticals and serving as Chairman and CEO of Enumeral Biomedical.
Through his personal and professional experience, Mr. Fayad developed a deep appreciation for authenticity to build long term value.
Outside of work, he enjoys the outdoors, reading, and spending time with friends and family.
He holds a Bachelor of Science in Biology from the American University of Beirut and an MBA from Concordia University.
Aktive Positionen von Wael Fayad
| Unternehmen | Position | Beginn |
|---|---|---|
Hildred Capital Management LLC
 Hildred Capital Management LLC Investment ManagersFinance Hildred Capital Management LLC (Hildred Capital) is a private equity firm founded in 2014 by David Solomon and Andrew Goldman. The firm is headquartered in New York. | Private Equity Investor | 01.05.2018 |
Crown Laboratories, Inc.
 Crown Laboratories, Inc. Pharmaceuticals: OtherHealth Technology Crown Laboratories, Inc. provides pharmaceutical and consumer products. Its products include aesthetics, beauty, therapeutic and prescription products. The firm offers contract development, manufacturing, production and packaging servicers. The company was founded by Don Kilday and Jeff Bedard in November 2000 and is headquartered in Johnson City, TN. | Direktor/Vorstandsmitglied | 01.02.2020 |
Ehemalige bekannte Positionen von Wael Fayad
| Unternehmen | Position | Ende |
|---|---|---|
| Accoy Pharmaceuticals, Inc. | Gründer | 01.09.2019 |
| ENUMERAL BIOMEDICAL HOLDINGS INC | Vorstandsvorsitzender | 29.06.2017 |
| FOREST LABORATORIES, INC. | Corporate Officer/Principal | - |
Ausbildung von Wael Fayad
| Concordia University | Masters Business Admin |
| American University of Beirut | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Crown Laboratories, Inc.
Crown Laboratories, Inc. Pharmaceuticals: OtherHealth Technology Crown Laboratories, Inc. provides pharmaceutical and consumer products. Its products include aesthetics, beauty, therapeutic and prescription products. The firm offers contract development, manufacturing, production and packaging servicers. The company was founded by Don Kilday and Jeff Bedard in November 2000 and is headquartered in Johnson City, TN. | Health Technology |
Forest Laboratories, Inc.
 Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Forest Laboratories, Inc. is engaged in the development, manufacture, and sale of branded forms of drug products. Its products include Bystolic, which is used to decrease heart rate and myocardial contractility; Daliresp, which is used to reduce the risk of chronic obstructive pulmonary disease exacerbation; Linzess, which is used in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; and Namenda, which is used in the treatment of moderate to severe dementia. The company was founded in 1954 and is headquartered in New York, NY. | Health Technology |
Enumeral Biomedical Holdings, Inc.
 Enumeral Biomedical Holdings, Inc. BiotechnologyHealth Technology Enumeral Biomedical Holdings, Inc. is a biopharmaceutical company, which engages in the business of discovering and developing novel antibody immunotherapies for the treatment of cancer and other diseases. It also focuses on the development of a pipeline of next generation monoclonal antibody drugs targeting established and novel immuno-modulatory receptors. The company was founded by Barry C. Buckland, John J. Rydzewski, and Arthur H. Tinkelenberg on December 11, 2009 and is headquartered in Arlington, MA. | Health Technology |
Hildred Capital Management LLC
Hildred Capital Management LLC Investment ManagersFinance Hildred Capital Management LLC (Hildred Capital) is a private equity firm founded in 2014 by David Solomon and Andrew Goldman. The firm is headquartered in New York. | Finance |
| Accoy Pharmaceuticals, Inc. |
